In response to Bergonzi et al.: Azacitidine–ruxolitinib combination therapy may permit dose reduction in VEXAS syndrome

Key Points

• This research explores how azacitidine and ruxolitinib combination therapy may allow for lower dosing in treating VEXAS syndrome.
• Assessment of therapy effects on VEXAS syndrome.
• Evaluation of dose adjustments during treatment.
• Combination therapy may reduce the required dose for effective treatment.
• Potential improvements in patient outcomes with lower medication dosages.